By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Surrozen, Inc.

Surrozen, Inc. (SRZN)

NASDAQ Currency in USD
$11.41
-$0.43
-3.59%
Last Update: 11 Sept 2025, 20:00
$97.79M
Market Cap
-0.86
P/E Ratio (TTM)
Forward Dividend Yield
$5.90 - $18.17
52 Week Range

SRZN Stock Price Chart

Explore Surrozen, Inc. interactive price chart. Choose custom timeframes to analyze SRZN price movements and trends.

SRZN Company Profile

Discover essential business fundamentals and corporate details for Surrozen, Inc. (SRZN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

11 Jan 2021

Employees

40.00

CEO

Craig C. Parker

Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

SRZN Financial Timeline

Browse a chronological timeline of Surrozen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 5 Nov 2025

EPS estimate is -$1.17.

Earnings released on 8 Aug 2025

EPS came in at -$1.14 surpassing the estimated -$1.23 by +7.32%, while revenue for the quarter reached $983.00K .

Earnings released on 9 May 2025

EPS came in at -$3.13 falling short of the estimated -$1.09 by -187.16%, while revenue for the quarter reached $983.00K .

Earnings released on 31 Mar 2025

EPS came in at -$9.10 falling short of the estimated -$2.54 by -258.27%, while revenue for the quarter reached $655.00K .

Earnings released on 6 Nov 2024

EPS came in at -$0.44 surpassing the estimated -$2.77 by +84.12%, while revenue for the quarter reached $10.00M .

Earnings released on 12 Aug 2024

EPS came in at -$1.54 surpassing the estimated -$2.79 by +44.80%.

Earnings released on 8 May 2024

EPS came in at -$4.24 surpassing the estimated -$4.25 by +0.24%.

Earnings released on 27 Mar 2024

EPS came in at -$4.41 falling short of the estimated -$3.00 by -47.00%, while revenue for the quarter reached $4.15M .

Stock split effective on 14 Dec 2023

Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 8 Nov 2023

EPS came in at -$4.35 falling short of the estimated -$4.20 by -3.57%.

Earnings released on 9 Aug 2023

EPS came in at -$4.65 surpassing the estimated -$6.00 by +22.50%.

Earnings released on 10 May 2023

EPS came in at -$7.20 falling short of the estimated -$5.10 by -41.18%.

Earnings released on 22 Mar 2023

EPS came in at -$0.45 surpassing the estimated -$6.75 by +93.33%, while revenue for the quarter reached $12.50M .

Earnings released on 14 Nov 2022

EPS came in at -$5.70 surpassing the estimated -$6.45 by +11.63%.

Earnings released on 11 Aug 2022

EPS came in at -$6.00 surpassing the estimated -$6.90 by +13.04%.

Earnings released on 11 May 2022

EPS came in at -$3.45 surpassing the estimated -$8.10 by +57.41%.

Earnings released on 24 Mar 2022

EPS came in at -$5.25 surpassing the estimated -$7.80 by +32.69%.

Earnings released on 15 Nov 2021

EPS came in at -$0.51 falling short of the estimated -$0.38 by -34.21%.

Earnings released on 6 Aug 2021

EPS came in at -$0.36 .

Earnings released on 15 Jul 2021

EPS came in at -$0.37 .

Earnings released on 31 Mar 2021

EPS came in at -$0.31 .

Earnings released on 4 Jan 2021

EPS came in at -$0.25 .

SRZN Stock Performance

Access detailed SRZN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run